NovaBay regains from Alcon rights to novel antimicrobials
This article was originally published in Scrip
Executive Summary
NovaBay Pharmaceuticals has regained from Alcon worldwide rights to a series of synthetic N-chlorinated antimicrobials, aganocides, that mimic the body's natural defences. This includes the worldwide technology license for lead compound NVC-222 in an eye drop formulation.